MiR-4326 predicts adverse outcomes of triple-negative breast cancer and regulates cell growth and motility through modulating MED13.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is one of the most malignant subtypes of breast cancer with a high recurrence rate and adverse prognosis. Due to the lack of reliable molecular targets, improving patients' outcomes is still a challenge in the clinic. The clinical significance of miR-4326 and its potential in mediating tumor progression were investigated in this study, aiming to explore a novel biomarker for TNBC.

Methods

A total of 108 patients diagnosed with TNBC were included in the present study, and the tissue samples were collected. The expression of miR-4326 was evaluated using PCR, while its clinical significance was assessed from the perspectives of disease severity and 5-year prognosis. In vitro, the regulation of TNBC cell growth and motility by miR-

SUBMITTER: Wang W 

PROVIDER: S-EPMC12918289 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature